References
- WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020 [Internet]. World Health Organisation; 2020 Mar 11 [cited 2020 Dec 7]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020.
- Coronavirus disease (COVID-19). Situation Report – 198. World Health Organisation; 2020 Aug 5 [cited 2020 Dec 7]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200805-covid-19-sitrep-198.pdf? sfvrsn = f 99d1754_2.
- Singh TU, Parida S, Lingaraju MC, et al. Drug repurposing approach to fight COVID-19. Pharmacol Rep. 2020;72(6):1479–1508.
- FDA approves first treatment for COVID-19 [Internet]. U.S. Food & Drug Administration; 2020 Oct 22 [cited 2020 Dec 21]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19.
- Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine [Internet]. U.S. Food & Drug Administration; 2020 Jun 15 [cited 2020 Dec 21]; Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and.
- Jorge A. Hydroxychloroquine in the prevention of COVID-19 mortality. Lancet Rheumatol. 2021;3(1):e2–e3.
- Ahmed S, Karim MM, Ross AJ, et al. A five day course of Ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214–216.
- Effectiveness of Ivermectin and Doxycycline on COVID-19 patients [Internet]. U.S. National Library of Medicine; National Institutes of Health; 2020 Oct 19 [cited 2020 Dec 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04591600.
- Joshi S, Parkar J, Ansari A, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021 Jan;102:501–508.
- Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021;103:62–71.
- Haleeqa MA, Alshamsi I, Al Habib A, et al. Optimizing supportive care in COVID-19 patients: a multidisciplinary approach. J Multidiscip Heal. 2020;13:877–880.
- COVID-19 Vaccines [Internet]. U.S. Food & Drug Administration; 2021 Jul 16 [cited 2021 Jul 9]. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines.
- Baron SA, Devaux C, Colson P, et al. Teicoplanin: an alternative drug for the treatment of COVID-19? Int J Antimicrob Agents. 2020;55(4):105944.
- Prajapat M, Sarma P, Shekhar N, et al. Drug targets for corona virus: a systematic review. Indian J Pharmacol. 2020;52(1):56–65.
- Bergmann CC, Silverman RH. COVID-19: coronavirus replication, pathogenesis, and therapeutic strategies. Cleve Clin J Med. 2020;87(6):321–327.
- Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 2014;281(18):4085–4096.
- Hosseini FS, Amanlou M. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: virtual screening, molecular docking, and molecular dynamics simulation study. Life Sci. 2020;258:118205.
- Mirza MU, Froeyen M. Structural elucidation of SARS-CoV-2 vital proteins: computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. J Pharm Anal. 2020;10(4):320–328.
- Alnajjar R, Mostafa A, Kandeil A, et al. Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease. Heliyon. 2020;6(12):e05641.
- Zhang L, Jackson C, Mou H, et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020;11(1):6013.
- Wang R, Hozumi Y, Yin C, et al. Mutations on COVID-19 diagnostic targets. Genomics. 2020;112(6):5204–5213.
- Berrio A, Gartner V, Wray GA. Positive selection within the genomes of SARS-CoV-2 and other coronaviruses independent of impact on protein function. PeerJ. 2020;8:e10234.
- Tang JW, Tambyah PA, Hui DS, et al. Emergence of a new SARS-CoV-2 variant in the UK. J Infect. 2021;82(4):e27–e28.
- Garvey MI, McMurray C, Casey AL, et al. Observations of SARS-CoV-2 variant of concern B.1.1.7 at the UK’s largest hospital trust. J Infect. 2021;83(4):e21–e23.
- Mhatre S, Gurav N, Shah M, et al. Entry-inhibitory role of catechins against SARS-CoV-2 and its UK variant. Comput Biol Med. 2021;135:104560.
- Kumar S. Second wave of COVID-19: emergency situation in India. J Travel Med. 2021;28(7):taab082.
- Callaway E. Delta coronavirus variant: scientists brace for impact. Nature. 2021;595(7865):17–18.
- Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276–280.
- SARS-CoV-2 variants of concern and variants under investigation [Internet]. Technical Briefing 15. Public Health England. 2021 Jun 11 [cited 2021 Jul 11]. Available from: https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201.
- Tracking SARS-CoV-2 variants. World Health Organisation. 2021 Jul 23 [cited 2021 Jul 11]. Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants/tracking-SARS-CoV-2-variants.
- Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280. e8.
- Shirato K, Kawase M, Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol. 2013;87(23):12552–12561.
- Hamming I, Timens W, Bulthuis MLC, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–637.
- Shen LW, Mao HJ, Wu YL. TMPRSS2: a potential target for treatment of influenza virus and coronavirus infections. Biochimie. 2017;142:1–10.
- Yamamoto M, Matsuyama S, Li X, et al. Identification of Nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus s protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob Agents Chemother. 2016;60(11):6532–6539.
- Hoffmann M, Schroeder S, Kleine-Weber H, et al. Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother. 2020;64(6):e00754–20.
- Antalis TM, Bugge TH, Wu Q. Membrane-anchored serine proteases in health and disease. Prog Mol Biol Transl Sci. 2011;99:1–50.
- Wilson S, Greer B, Hooper J, et al. The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Biochem J. 2005;388(Pt 3):967–972.
- Ko CJ, Huang CC, Lin HY, et al. Androgen-induced TMPRSS2 activates matriptase and promotes extracellular matrix degradation, prostate cancer cell invasion, tumor growth, and metastasis. Cancer Res. 2015;75(14):2949–2960.
- Lucas JM, Heinlein C, Kim T, et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 2014;4(11):1310–1325.
- Hedstrom L. Serine protease mechanism and specificity. Chem Rev. 2002;102(12):4501–4524.
- Tang J, Yu CL, Williams SR, et al. Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma kallikrein. J Biol Chem. 2005;280(49):41077–41089.
- Maccari R, Ottanà R, Ciurleo R, et al. Synthesis, induced-fit docking investigations, and in vitro aldose reductase inhibitory activity of non-carboxylic acid containing 2,4-thiazolidinedione derivatives. Bioorg Med Chem. 2008 Jun 1;16(11):5840–5852.
- Kashyap K, Kakkar R. Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors. Comput Biol Med. 2020;123:103850.
- Farid R, Day T, Friesner RA. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. Bioorg Med Chem. 2006;14(9):3160–3173.
- Sherman W, Beard HS, Farid R. Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Des. 2006;67(1):83–84.
- Sherman W, Day T, Jacobson MP, et al. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem. 2006;49(2):534–553.
- Jacobson MP, Friesner RA, Xiang Z, et al. On the role of the crystal environment in determining protein side-chain conformations. J Mol Biol. 2002;320(3):597–608.
- Jacobson MP, Pincus DL, Rapp CS, et al. A hierarchical approach to all-atom protein loop prediction. Proteins. 2004;55(2):351–367.
- Ylilauri M, Pentikäinen OT. MMGBSA as a tool to understand the binding affinities of filamin–peptide interactions. J Chem Inf Model. 2013;53(10):2626–2633.
- Li J, Abel R, Zhu K, et al. The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. Proteins. 2011;79(10):2794–2812.
- Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017;46:D1074–D1082.
- Waterhouse A, Bertoni M, Bienert S, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46(W1):W296–W303.
- Yadav R, Deepshikha D, Srivastava P. Homology modeling and protein interaction map of CHRNA7 neurogenesis protein. Ann Neurosci. 2017;24(3):173–179.
- Patschull AOM, Gooptu B, Ashford P, et al. In silico assessment of potential druggable pockets on the surface of α1-antitrypsin conformers. PLoS One. 2012;7(5):e36612.
- Schulz-Gasch T, Stahl M. Binding site characteristics in structure-based virtual screening: evaluation of current docking tools. J Mol Model. 2003;9(1):47–57.
- Halgren TA. Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model. 2009;49(2):377–389.
- Lobo MJ, Ray R, Shenoy GG. Gaining deeper insights into the surface binding of bedaquiline analogues with the ATP synthase subunit C of Mycobacterium tuberculosis using molecular docking, molecular dynamics simulation and 3D-QSAR techniques. New J Chem. 2020;44:18831–18852.
- Martyna GJ, Tobias DJ, Klein ML. Constant pressure molecular dynamics algorithms. J Chem Phys. 2006;124(10):104102.
- Ivanova L, Tammiku-Taul J, García-Sosa AT, et al. Molecular dynamics simulations of the interactions between glial cell line-derived neurotrophic factor family receptor GFRα1 and small-molecule ligands. ACS Omega. 2018;3(9):11407–11414.
- Bowers KJ, Chow E, Xu H, et al. Scalable algorithms for molecular dynamics simulations on commodity clusters. 2007 Nov 11-17; Tampa, FL Proceedings of the 2006 ACM/IEEE Conference on Supercomputing; 2006, p 43–43.
- Sisay M. Available evidence and ongoing clinical trials of remdesivir: could it be a promising therapeutic option for COVID-19? Front Pharmacol. 2020;11:791, Published 2020 May 26. doi:10.3389/fphar.2020.00791.
- Le N, Meier C. Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase. bioRxiv [Preprint]. 2020. 2020.05.15.098731
- Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
- Ko M, Jeon S, Ryu WS, et al. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021;93(3):1403–1408.
- Maruyama Y, Yoshida H, Uchino S, et al. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: A three-year retrospective cohort study. Int J Artif Organs. 2011;34(7):571–576.
- CAMOSTAT [Internet]. Inxight:Drugs. National Center for Advancing Translational Sciences. National Institutes of Health. U.S. Department of Health & Human Services. Available from: https://drugs.ncats.io/substance/0FD207WKDU.
- Tuberculosis and COVID-19 [Internet]. World Health Organization. 2021 [cited 2021 Mar 13]. Available from: https://www.who.int/teams/global-tuberculosis-programme/covid-19.
- Luo J, Rizvi H, Preeshagul IH, et al. COVID-19 in patients with lung cancer. Ann Oncol. 2020;31(10):1386–1396.
- Treatment of Tuberculosis: Guidelines. 4th ed. Geneva: World Health Organization; 2010 [cited 2020 Dec 7]. A1, Essential first-line antituberculosis drugs. Available from: https://www.ncbi.nlm.nih.gov/books/NBK138747/.
- Vatsyayan R, Chaudhary P, Lelsani PCR, et al. Role of RLIP76 in doxorubicin resistance in lung cancer (review). Int J Oncol. 2009;34(6):1505–1511.